Alert
Close

Take AARP’s Smart Driver course and you could save money on your car insurance. Learn more

HIGHLIGHTS

Open

AUTO BUYING PROGRAM

AARP Auto Buying Program

Download the ipad App

AARP-iPad-ePub-app

DRIVER SAFETY

Piggy bank on the road - AARP Driver Safety

Take the new AARP Smart Driver Course!

Contests and
Sweeps

Safe Driving in 2014 Sweepstakes

Learn how AARP Driver Safety can help you stay safe—and enter for a chance to win $1,000. See official rules. 

KEEP BRAIN ACTIVE!

AARP Games - Play Now!

AARP BOOKS

Planning for Long-Term Care for Dummies

Get expert advice on planning for your own or a relative’s future care needs.

Webinars

Learn From the Experts

Sign up now for an upcoming webinar or find materials from a past session.

Learning centers

Get smart strategies for managing health conditions.

 

Arthritis

Heart Disease

Diabetes

Most Popular

Viewed

share your thoughts

What does the health care law mean to you? Your story is important. We read and learn from every story and it helps us in our educational efforts. We may even use your comments (with permission) to brief legislators, inspire readers and more. Please share your story with us. Do

New Test Could Help Detect Alzheimer’s Disease

Who should get it?

A negative scan, says Weiner, could be reassuring. "Let's say I have a person that's having quite a bit of memory problems, but the scan is negative. Well, that's good news. That's very good news. They are very unlikely to show a rapid deterioration from Alzheimer's."

The new tracer scans "should not be used in everybody," says James E. Galvin, M.D., director of the Pearl Barlow Center for Memory Evaluation and Treatment at New York University's Langone Medical Center. He says if the patient has symptoms consistent with Alzheimer's and the doctor is confident of the diagnosis, the scan would add little information.

Its utility, he believes, will be in helping to resolve "diagnostic dilemmas" where symptoms and other findings leave significant room for doubt. And in tracking the effects of experimental drugs.

One more tool to help with a cure

Finding Alzheimer’s early is critical both to discovering treatments that attack the disease—currently there are none—and not just its symptoms. Researchers believe the damage in the brain begins a decade or more before an individual notices symptoms. Indeed, it may be that many experimental drugs have failed to arrest or even slow Alzheimer’s because they came too late; dead brain cells don’t come back to life.

The new amyloid tracer (florbetapir F18) represents only one of several recent advances in techniques for observing Alzheimer’s disease in the brain, says Maria C. Carrillo, senior director for medical and scientific relations for the Alzheimer’s Association, host of the conference in Honolulu. “What’s exciting about our current state of knowledge,” she says, “is that we now understand that early detection is possible. That gives us so much hope.”

Other tests that measure signs of Alzheimer’s—from key proteins in spinal fluid to other kinds of imaging—seem to offer a telling glimpse into the disease at different points along its destructive path through the brain. Each may prove a useful source of information at different stages of Alzheimer’s.

The new tracer builds on scientific pioneering by University of Pittsburgh researchers who developed an agent that helped spotlight plaque in the brain. But their compound has a very short life and can only be used by high-tech research centers. Use by doctors in hospitals and clinics is out of the question.

Avid’s new tracer, on the other hand, lasts long enough to allow its transport from manufacturing sites to scanning clinics, potentially reaching about 90 percent of the country, says company spokesperson Christopher Bunting.

Will it be covered by insurance?

For these new brain scans to enter widespread use, both experts and insurers will need to be convinced that they provide some clear benefit—making it easier for patients to get treatment, for example.

Currently the standard evaluation for possible Alzheimer’s disease includes some type of brain imaging—a CT (computed tomography) or MRI—mostly to rule out other problems such as a stroke or tumor.

The more specialized PET test is used far less often, and is covered by Medicare only for the specific purpose of distinguishing Alzheimer’s from a relatively rare condition called fronto-temporal dementia, which typically produces quite different findings on the scan.

Next: How is this test beneficial in preventing Alzheimer's? >>

Topic Alerts

You can get weekly email alerts on the topics below. Just click “Follow.”

Manage Alerts

Processing

Please wait...

progress bar, please wait

Tell Us WhatYou Think

Please leave your comment below.

Discounts & Benefits

From companies that meet the high standards of service and quality set by AARP.

Woman trying on glasses in optometrists shop

Members save up to 60% on eye exams and 30% on glasses at JCPenney Optical.

Prescription medication spilling out of bottle

Members get a free Rx card from AARP® Prescription Discounts provided by Catamaran.

AngiesList

Members can save 25% to 45% on their Angie's List membership.

Caregiving walking

Caregiving can be a lonely journey, but AARP offers resources that can help.